BioCentury | Apr 1, 2010
Cover Story

Putting fat in its place

...acquired a VEGF-B mAb program as part of its 2006 purchase of fellow Australian biotech Zenyth Therapeutics Ltd....
...Ltd. on uncovering VEGF-B's function. Nash said that this 10-year-long collaboration has continued now that Zenyth...
BioCentury | Nov 3, 2008
Company News

MuriGen, CSL deal

...disclose the clinical status of any resulting compounds. The original deal was between MuriGen and Zenyth Therapeutics Ltd....
BioCentury | Jun 25, 2007
Company News

Benitec scientific advisory board update

...David Crump, formerly head of development projects and medical advisor at Amrad Corporation Ltd. (now Zenyth Therapeutics Ltd....
BioCentury | May 28, 2007
Tools & Techniques

Catching up to GM-CSF

...AZN completes its acquisition of Cambridge Antibody Technology plc. CAT, which is collaborating with CSL's Zenyth Therapeutics Ltd....
BioCentury | Sep 18, 2006
Company News

CSL, Zenyth deal

...will meet on Oct. 23 to vote on the acquisition. CSL Ltd. (ASX:CSL), Melbourne, Australia Zenyth Therapeutics Ltd....
BioCentury | Jul 24, 2006
Finance

Ebb & Flow

...see "Endocrine Boosting," A9). Meanwhile, CSL (ASX:CSL) is also shelling out a premium to acquire Zenyth...
BioCentury | Jul 24, 2006
Strategy

From A to Z to CSL

...Two decades after it was founded and one decade after it went public, Zenyth Therapeutics Ltd. is being...
...being acquired by fellow Australian company CSL Ltd. for A$102.7 million ($77.3 million) in cash. Zenyth...
...year, and the stock has not risen above A$1 since. Amrad changed its name to Zenyth...
BioCentury | Jul 24, 2006
Company News

CSL, Zenyth deal

...is being acquired by AstraZeneca plc (LSE:AZN; AZN, London, U.K.). CSL Ltd. (ASX:CSL), Melbourne, Australia Zenyth Therapeutics Ltd....
BioCentury | Jul 18, 2006
Company News

CSL to acquire Zenyth

...CSL (ASX:CSL) will acquire Zenyth (ASX:ZTL) for A$0.82 per share, or about A$102.7 million (US$77.3 million...
BioCentury | May 29, 2006
Company News

Zenyth, Merck deal

...a preclinical IL-13 receptor antibody to treat asthma, did not disclose what triggered the milestone. Zenyth Therapeutics Ltd....
Items per page:
1 - 10 of 17
BioCentury | Apr 1, 2010
Cover Story

Putting fat in its place

...acquired a VEGF-B mAb program as part of its 2006 purchase of fellow Australian biotech Zenyth Therapeutics Ltd....
...Ltd. on uncovering VEGF-B's function. Nash said that this 10-year-long collaboration has continued now that Zenyth...
BioCentury | Nov 3, 2008
Company News

MuriGen, CSL deal

...disclose the clinical status of any resulting compounds. The original deal was between MuriGen and Zenyth Therapeutics Ltd....
BioCentury | Jun 25, 2007
Company News

Benitec scientific advisory board update

...David Crump, formerly head of development projects and medical advisor at Amrad Corporation Ltd. (now Zenyth Therapeutics Ltd....
BioCentury | May 28, 2007
Tools & Techniques

Catching up to GM-CSF

...AZN completes its acquisition of Cambridge Antibody Technology plc. CAT, which is collaborating with CSL's Zenyth Therapeutics Ltd....
BioCentury | Sep 18, 2006
Company News

CSL, Zenyth deal

...will meet on Oct. 23 to vote on the acquisition. CSL Ltd. (ASX:CSL), Melbourne, Australia Zenyth Therapeutics Ltd....
BioCentury | Jul 24, 2006
Finance

Ebb & Flow

...see "Endocrine Boosting," A9). Meanwhile, CSL (ASX:CSL) is also shelling out a premium to acquire Zenyth...
BioCentury | Jul 24, 2006
Strategy

From A to Z to CSL

...Two decades after it was founded and one decade after it went public, Zenyth Therapeutics Ltd. is being...
...being acquired by fellow Australian company CSL Ltd. for A$102.7 million ($77.3 million) in cash. Zenyth...
...year, and the stock has not risen above A$1 since. Amrad changed its name to Zenyth...
BioCentury | Jul 24, 2006
Company News

CSL, Zenyth deal

...is being acquired by AstraZeneca plc (LSE:AZN; AZN, London, U.K.). CSL Ltd. (ASX:CSL), Melbourne, Australia Zenyth Therapeutics Ltd....
BioCentury | Jul 18, 2006
Company News

CSL to acquire Zenyth

...CSL (ASX:CSL) will acquire Zenyth (ASX:ZTL) for A$0.82 per share, or about A$102.7 million (US$77.3 million...
BioCentury | May 29, 2006
Company News

Zenyth, Merck deal

...a preclinical IL-13 receptor antibody to treat asthma, did not disclose what triggered the milestone. Zenyth Therapeutics Ltd....
Items per page:
1 - 10 of 17